Wegovy and Head Pressure: What You Need to Know

What the STEP 1 trial data recorded about headache

The STEP 1 trial (the pivotal phase 3 study of semaglutide 2.4mg, published in the New England Journal of Medicine) enrolled 1,961 adults with obesity over 68 weeks. Headache was documented as an adverse event in the semaglutide arm at a rate that exceeded the placebo group. In the broader STEP programme, gastrointestinal effects dominated the safety profile, but headache consistently appeared as a nervous-system side effect alongside nausea, dizziness and fatigue.

The pattern the data reveal is consistent: head-related symptoms tend to cluster around the start of treatment and around each dose step. The body is adapting to slower gastric emptying, shifting energy intake and altered fluid balance. That adaptation period rarely lasts more than one to two weeks at each stage for most people, though individual experience varies.

The NHS medicines page for semaglutide lists headache under common side effects (meaning it occurs in more than one in a hundred people) and notes that these effects are usually mild to moderate. It does not class head pressure specifically, because "pressure" is a subjective description that may overlap with headache, tension or, less commonly, something worth a closer look from a clinician.

Why head pressure may feel different from an ordinary headache

Several mechanisms may explain why the sensation some people describe goes beyond a typical tension headache. Reduced calorie and fluid intake in the early weeks of treatment can cause mild dehydration. Dehydration lowers blood volume slightly, which can trigger vasodilation (blood vessels widening to compensate) and that produces the throbbing, pressured quality that many people recognise as a dehydration headache.

There is also the question of blood pressure. Semaglutide produces meaningful reductions in blood pressure in many people, and a rapid shift in blood pressure can itself cause head symptoms, particularly on standing or moving quickly. If you are wondering whether Wegovy helps with blood pressure and what the evidence actually shows, that page covers the topic in detail. If you want to understand more about how Wegovy affects blood pressure and what those changes actually involve, that page covers the mechanisms in more depth.

A small number of people taking GLP-1 medicines have reported changes in eye pressure — a separate question from head pressure but one that can overlap in how it presents. Anyone who notices visual disturbance, eye pain, or pressure that feels centred around the eye socket should speak to a clinician promptly. The question of Wegovy and eye pressure has its own dedicated page if that is closer to your concern.

One practical note our prescribers hear regularly: people sometimes forget to drink enough during the day when appetite and thirst cues are both suppressed by semaglutide. Keeping a water bottle somewhere visible (on the desk, next to the kettle) makes a real difference to symptom burden in the first few weeks.

When to seek medical help rather than wait it out

Most head pressure on Wegovy is benign and time-limited. There are, however, situations where you should seek medical attention the same day rather than monitor at home.

Contact your GP or NHS 111 if your headache is the worst you have ever experienced, comes on very suddenly, is accompanied by visual changes or loss of vision, weakness or numbness on one side, difficulty speaking, or is associated with a stiff neck and sensitivity to light. These features are not typical of a semaglutide-related headache and need prompt assessment.

The MHRA's Yellow Card scheme allows patients to report suspected side effects from any medicine, including Wegovy, at yellowcard.mhra.gov.uk. Reporting is straightforward and helps build the evidence base that regulators use to update safety guidance over time. You do not need a confirmed diagnosis to submit a report, a suspicion is enough.

If head pressure is persistent, severe or getting worse rather than settling, let your prescribing team know before your next scheduled check-in rather than waiting. At nume, aftercare is available seven days a week, use it. You can also read more broadly about how Wegovy works and what to expect during treatment, or explore the wider landscape of weight-loss treatment options if you are still deciding which medicine might suit you.

Practical steps that tend to reduce head pressure on semaglutide

While the evidence base for specific management strategies is largely drawn from general headache and dehydration research rather than dedicated GLP-1 trials, the following are consistent with NHS guidance and with what prescribers observe in practice.

Prioritise fluids. Aiming for around two litres of water across the day is a reasonable starting point during the early weeks of treatment. If nausea is making this difficult, small, frequent sips tend to be better tolerated than large volumes at once.

Avoid common headache triggers during the adjustment period, irregular sleep, skipped meals and caffeine fluctuations can all compound the effect. Paracetamol is generally appropriate for short-term relief; ibuprofen and other NSAIDs should only be used after checking with a pharmacist or prescriber, as they carry their own considerations alongside GLP-1 therapy.

Track the pattern. If head pressure consistently arrives one to two days after your weekly injection and resolves within a few days, that temporal relationship is useful information for your prescriber, and it is also worth being aware that Wegovy and high blood pressure interact in ways that can be relevant to how those post-injection symptoms present. It suggests a post-injection adaptation response rather than anything unrelated to the medicine.

For a fuller picture of cardiovascular measures, our page on Wegovy and blood pressure, covering what changes to expect and how to keep track of them, is a related question worth reading alongside this one. And if you are weighing up starting treatment, our consultation page is the right place to begin a conversation with a prescriber.